Accelovance, a Rockville, Maryland-based company with a wholly foreign owned enterprise (WFOE) in China celebrates the opening of an office in Shanghai, its second in the PR China.

    With additional presence in China's pharmaceutical market, the Shanghai office allows Accelovance to broaden its services and expand its capacity for conducting Phase I-IV clinical trials.

    "Accelovance has a growing presence as a full service contract research organization (CRO) in China and the opening of a new office is evidence of that. It gives us a greater opportunity to service pharma and biotech companies on an international level," commented President and CEO Stephen J. Trevisan.  Accelovance will take office space with the State of Maryland in Shanghai, immediately employing 3-5 clinical personnel.  In recent years, the State of Maryland has proactively worked with locally based companies to promote growth in emerging markets, such as China.  Mary Kane, Maryland's Secretary of State, agrees, "Maryland has embraced the idea of global cooperative ventures.  Accelovance is an excellent example of future opportunities for the business community in Maryland and abroad."

    Accelovance's Beijing office will continue to serve as the base of operations for China, managing the new Shanghai location.  Operations in China provide Accelovance's clients with a strategic alternative to their clinical trial needs and add to the capabilities of an existing 10-site network in the United States.  Dr. Ken Ren, President of Accelovance China noted, "Since our Beijing office opened in May, our services in China have been well received.

   Now with a location in another region of the country, Accelovance is better positioned to rapidly enroll patients and conduct trials in a cost effective manner."

    Headquartered in Rockville, Maryland, Accelovance is a privately held company that has 10 clinical sites in the United States.  In China, the Company operates through its wholly owned foreign enterprise in Beijing and has established clinical services in the country.  Globally, Accelovance provides Phase I-IV clinical trial services across a focus of therapeutic areas that include investigator selection, patient recruitment and study management services for pharmaceutical, contract research organization (CRO), and biotechnology industries. The company is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment.  Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to ensure their success.

    For more information, visit the company's website at http://www.accelovance.com.